Last reviewed · How we verify
nanoparticulate paclitaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
nanoparticulate paclitaxel (nanoparticulate paclitaxel) — CritiTech, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| nanoparticulate paclitaxel TARGET | nanoparticulate paclitaxel | CritiTech, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- nanoparticulate paclitaxel CI watch — RSS
- nanoparticulate paclitaxel CI watch — Atom
- nanoparticulate paclitaxel CI watch — JSON
- nanoparticulate paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). nanoparticulate paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/nanoparticulate-paclitaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab